Benötigen Sie weitere Informationen?
With the automated qualitative VIDAS ® SARS-COV-2 IgM and VIDAS ® SARS-COV-2 IgG tests, antibodies can be quickly detected in order to determine whether people have already had contact with the SARS-CoV-2 pathogen.
Severe Acute Respiratory Syndrome - Coronavirus 2 (SARS-CoV-2) is a novel coronavirus that was discovered in China in December 2019 and has led to an unprecedented global pandemic. It causes COVID-19 ( Corona virus disease 19), a respiratory disease that can present with mild to severe symptoms that can lead to pneumonia, multi-organ failure, or even death. Identifying people who have been infected with this new virus is key to providing better medical care and managing the COVID-19 health crisis
VIDAS ® SARS-COV-2 IgM (9COM) and VIDAS ® SARS-COV-2 IgG (9COG) combine an immunoenzymatic sandwich method with a final fluorescence measurement (ELFA). The tests can be performed on any VIDAS ® device and offer flexibility and reliable results in less than 30 minutes .
VIDAS ® SARS-COV-2 IgG II | VIDAS ® SARS-COV-2 IgM | |
---|---|---|
Order number | 424114 | 423833 |
Number of tests / kit | 60 | |
Time until the result is available | 27 minutes | |
sample type | Serum, plasma (lithium heparin) | |
sample volume | 100 µL | |
Result interpretation (i = index) | i <1 negative (no detection of IgM/ IgG against SARS-CoV-2) i ≥1 positive (detection of IgM/ IgG against SARS-CoV-2) |
|
Calibration and control interval | 28 days | |
durability | 12 months | |
device | The tests can be carried out on all devices of the VIDAS ® family. | |
|
Für Fragen zur Produktverfügbarkeit wenden Sie sich bitte an Ihre bioMérieux Niederlassung.